Explore
Validate
Learn
ImmunoprecipitationAntibody data
- Antibody Data
- Antigen structure
- References [16]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA5-12867 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- ErbB3 Monoclonal Antibody (H3.90.6 (Ab90))
- Antibody type
- Monoclonal
- Antigen
- Recombinant protein fragment
- Description
- MA5-12867 targets HER-3 in FACS, IF, and IP applications and shows reactivity with Human samples. The MA5-12867 immunogen is extracellular fragment of recombinant human c-erbB-3/HER-3 oncoprotein.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- H3.90.6 (Ab90)
- Vial size
- 500 µL
- Concentration
- 0.2 mg/mL
- Storage
- 4° C
Submitted references Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas.
Muc4-ErbB2 complex formation and signaling in polarized CACO-2 epithelial cells indicate that Muc4 acts as an unorthodox ligand for ErbB2.
Associations of ErbB2, beta1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines.
Isolation of scFvs to in vitro produced extracellular domains of EGFR family members.
Cooperative interactions of HER-2 and HPV-16 oncoproteins in the malignant transformation of human mammary epithelial cells.
Cooperative interactions of HER-2 and HPV-16 oncoproteins in the malignant transformation of human mammary epithelial cells.
HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization.
Proliferation-differentiation relationships in the expression of heparin-binding epidermal growth factor-related factors and erbB receptors by normal and psoriatic human keratinocytes.
Alpha6beta1 integrin induces proteasome-mediated cleavage of erbB2 in breast cancer cells.
Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2.
Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol.
Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol.
Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo.
Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase.
Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase.
ErbB-4 ribozymes abolish neuregulin-induced mitogenesis.
Folgiero V, Avetrani P, Bon G, Di Carlo SE, Fabi A, Nisticò C, Vici P, Melucci E, Buglioni S, Perracchio L, Sperduti I, Rosanò L, Sacchi A, Mottolese M, Falcioni R
PloS one 2008 Feb 13;3(2):e1592
PloS one 2008 Feb 13;3(2):e1592
Muc4-ErbB2 complex formation and signaling in polarized CACO-2 epithelial cells indicate that Muc4 acts as an unorthodox ligand for ErbB2.
Ramsauer VP, Pino V, Farooq A, Carothers Carraway CA, Salas PJ, Carraway KL
Molecular biology of the cell 2006 Jul;17(7):2931-41
Molecular biology of the cell 2006 Jul;17(7):2931-41
Associations of ErbB2, beta1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines.
Mocanu MM, Fazekas Z, Petrás M, Nagy P, Sebestyén Z, Isola J, Tímár J, Park JW, Vereb G, Szöllosi J
Cancer letters 2005 Sep 28;227(2):201-12
Cancer letters 2005 Sep 28;227(2):201-12
Isolation of scFvs to in vitro produced extracellular domains of EGFR family members.
Horak E, Heitner T, Robinson MK, Simmons HH, Garrison J, Russeva M, Furmanova P, Lou J, Zhou Y, Yuan QA, Weiner LM, Adams GP, Marks JD
Cancer biotherapy & radiopharmaceuticals 2005 Dec;20(6):603-13
Cancer biotherapy & radiopharmaceuticals 2005 Dec;20(6):603-13
Cooperative interactions of HER-2 and HPV-16 oncoproteins in the malignant transformation of human mammary epithelial cells.
Woods Ignatoski KM, Dziubinski ML, Ammerman C, Ethier SP
Neoplasia (New York, N.Y.) 2005 Aug;7(8):788-98
Neoplasia (New York, N.Y.) 2005 Aug;7(8):788-98
Cooperative interactions of HER-2 and HPV-16 oncoproteins in the malignant transformation of human mammary epithelial cells.
Woods Ignatoski KM, Dziubinski ML, Ammerman C, Ethier SP
Neoplasia (New York, N.Y.) 2005 Aug;7(8):788-98
Neoplasia (New York, N.Y.) 2005 Aug;7(8):788-98
HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization.
Dragowska WH, Warburton C, Yapp DT, Minchinton AI, Hu Y, Waterhouse DN, Gelmon K, Skov K, Woo J, Masin D, Huxham LA, Kyle AH, Bally MB
Molecular cancer research : MCR 2004 Nov;2(11):606-19
Molecular cancer research : MCR 2004 Nov;2(11):606-19
Proliferation-differentiation relationships in the expression of heparin-binding epidermal growth factor-related factors and erbB receptors by normal and psoriatic human keratinocytes.
Piepkorn M, Predd H, Underwood R, Cook P
Archives of dermatological research 2003 Jul;295(3):93-101
Archives of dermatological research 2003 Jul;295(3):93-101
Alpha6beta1 integrin induces proteasome-mediated cleavage of erbB2 in breast cancer cells.
Shimizu H, Seiki T, Asada M, Yoshimatsu K, Koyama N
Oncogene 2003 Feb 13;22(6):831-9
Oncogene 2003 Feb 13;22(6):831-9
Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2.
Kunisue H, Kurebayashi J, Otsuki T, Tang CK, Kurosumi M, Yamamoto S, Tanaka K, Doihara H, Shimizu N, Sonoo H
British journal of cancer 2000 Jan;82(1):46-51
British journal of cancer 2000 Jan;82(1):46-51
Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol.
Aigner A, Hsieh SS, Malerczyk C, Czubayko F
Toxicology 2000 Apr 3;144(1-3):221-8
Toxicology 2000 Apr 3;144(1-3):221-8
Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol.
Aigner A, Hsieh SS, Malerczyk C, Czubayko F
Toxicology 2000 Apr 3;144(1-3):221-8
Toxicology 2000 Apr 3;144(1-3):221-8
Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo.
Tang CK, Concepcion XZ, Milan M, Gong X, Montgomery E, Lippman ME
Cancer research 1999 Oct 15;59(20):5315-22
Cancer research 1999 Oct 15;59(20):5315-22
Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase.
Adam L, Vadlamudi R, Kondapaka SB, Chernoff J, Mendelsohn J, Kumar R
The Journal of biological chemistry 1998 Oct 23;273(43):28238-46
The Journal of biological chemistry 1998 Oct 23;273(43):28238-46
Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase.
Adam L, Vadlamudi R, Kondapaka SB, Chernoff J, Mendelsohn J, Kumar R
The Journal of biological chemistry 1998 Oct 23;273(43):28238-46
The Journal of biological chemistry 1998 Oct 23;273(43):28238-46
ErbB-4 ribozymes abolish neuregulin-induced mitogenesis.
Tang CK, Goldstein DJ, Payne J, Czubayko F, Alimandi M, Wang LM, Pierce JH, Lippman ME
Cancer research 1998 Aug 1;58(15):3415-22
Cancer research 1998 Aug 1;58(15):3415-22
No comments: Submit comment
No validations: Submit validation data